According to Precedence Research, the global gRNA market size is expected to grow from USD 708.92 million in 2025 to nearly ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

CRISPR, the gene-editing technology which won its creators the 2020 Nobel Prize for Chemistry, is most well-known for its ...

Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Goldenberries taste like a cross between pineapple and mango, pack the nutritional punch of a superfood, and are increasingly ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to ...

But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...

Gene-edited crops are no safer than GMOs, and fast-tracking regulatory approval could trigger a costly backlash.

New research breaks down how scientists use CRISPR technology to lower cholesterol. The cholesterol-lowering effects could be permanent.